Vitrisa Therapeutics has entered into an option agreement with Ohr Pharmaceutical for certain rights to the data from the MAKO study in wet age-related macular degeneration.
Under the agreement, Vitrisa will receive initial nonexclusive rights to the data and a time-limited option to acquire worldwide exclusive ownership of the trial database. Vitrisa plans to use the data set to run virtual clinical trials and evaluate clinical strategies for wet AMD, according to a company press release.
The MAKO study was a 237-patient clinical trial to evaluate the efficacy and safety (Read more...)
Uncategorized